Nanobiotix S.A. (NASDAQ:NBTX – Free Report) – Stock analysts at Leerink Partnrs raised their FY2024 earnings per share estimates for Nanobiotix in a report issued on Tuesday, March 18th. Leerink Partnrs analyst J. Chang now expects that the company will post earnings of ($0.94) per share for the year, up from their prior estimate of ($1.22). The consensus estimate for Nanobiotix’s current full-year earnings is ($1.18) per share. Leerink Partnrs also issued estimates for Nanobiotix’s FY2025 earnings at ($0.51) EPS and FY2026 earnings at $0.84 EPS.
Separately, UBS Group raised Nanobiotix to a “hold” rating in a research report on Monday, February 17th.
Nanobiotix Stock Down 4.0 %
NBTX stock opened at $3.62 on Friday. The business has a 50-day moving average of $3.51 and a 200-day moving average of $3.90. Nanobiotix has a fifty-two week low of $2.76 and a fifty-two week high of $7.51.
Hedge Funds Weigh In On Nanobiotix
Large investors have recently made changes to their positions in the company. Geode Capital Management LLC bought a new position in shares of Nanobiotix during the fourth quarter worth approximately $29,000. Millennium Management LLC acquired a new stake in Nanobiotix during the fourth quarter worth approximately $39,000. Jane Street Group LLC acquired a new stake in Nanobiotix during the fourth quarter worth approximately $73,000. Finally, OLD Mission Capital LLC acquired a new stake in Nanobiotix during the fourth quarter worth approximately $139,000. Institutional investors own 38.81% of the company’s stock.
About Nanobiotix
Nanobiotix SA, a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer.
Read More
- Five stocks we like better than Nanobiotix
- The Significance of Brokerage Rankings in Stock Selection
- Why Williams-Sonoma Will Hit Fresh Highs in 2025
- How to Calculate Return on Investment (ROI)
- Alphabet Stock Becomes a Low-Risk, High-Reward Play
- What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story
- Affirm Stock: Should You Buy the Dip After Walmart Setback?
Receive News & Ratings for Nanobiotix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nanobiotix and related companies with MarketBeat.com's FREE daily email newsletter.
